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1. Introduction
1.1. Snake venom serine proteases
Serine proteases have been isolated from the venoms of viperidae snakes [1, 2] and affect
several physiological processes such as the coagulation cascade. These enzymes are called
snake venom serine proteases (SVSPs), they are multi-functional proteins with a catalytic triad
formed by HDS amino acids [3].
The SVSPs resembles at least in part thrombin, a multifunctional protease that plays a key role
in coagulation. Therefore these enzymes are denominated snake venom thrombin-like en‐
zymes (SVTLEs), and are widely distributed in the venoms of several genera [4,5]. While
thrombin is able to cleave both fibrinopeptide A (FPA) and fibrinopeptide B (FPB) from fibrino‐
gen leading the formation of fibrin and activating factor XIII, some actions of SVTLEs usually
cleave FPA alone and only a few cleave FPB. Thus, without cleavage of both FPA and FPB they
are unable to activate factor XIII producing fibrin monomers that are not cross-linked, leading
to clots markedly susceptible to digestion by plasmin and are rapidly removed from circulation
by either reticuloendothelial phagocitosis and/or normal fibrinolysis. This process causes a
breakdown in the fibrinolytic system and effective removal of fibrinogen from the plasma [6].
2. Body
There are three groups of snake venom fibrinogen clotting enzymes based on the rates of
release of fibrinopeptides A and/or B from fibrinogen. In addition to SVLTEs, other SVSPs
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groups are active in other parts of the coagulation cascade, such as kallikrein-like enzymes
(KN); plasminogen activators (PA); protein C like enzyme and factor V activators. One group
releases fibrinopeptide A preferentially (the venombin A group including ancrod from venom
of the Malayan pit viper, Calloselasma rhodostoma); another group releases both fibrinopeptides
A and B (the venombin AB group including halystase and calobin from Agkistrodon halys
blomhoffii and Agkistrodon caliginosus, respectively) and the third group releases fibrinopeptide
B preferentially (the venombin B group including v enzyme from venom of the southern
copperhead, Agkistrodon contortrix contortrix) [5,7,8]. Figure 1 summarizes some snake toxins
that affect the blood coagulation cascade, based on [6].
Figure 1. Some SVSPs acting in blood system. FGDP: Fibrinogen degradation products; FNDP: Fibrin degradation
products; FPA: Fibrinopeptide A; FPB: Fibrinopeptide B. KN-BJ, Bothrops jararaca (O13069) [9]; Dav-KN, Agkistrodon
acutus (Q9I8X0) [10]; Elegaxobin-1, Trimeresurus elegans (P84788) [11]; ACC-C Protein C activator; Agkistrodon con‐
tortrix contortrix (P09872) [12]; RVV-Vα Russel's viper venom FV activator alpha, Daboia russelli siamensis (P18964)
[13]; FVA Factor V-activating enzyme, Vipera lebetina (Q9PT41) [14]; Halystase, Agkistrodon halys blomhoffii
(P81176) [15]; Calobin, Agkistrodon caliginosus (Q91053) [16], Gyroxin-like B2.1, Crotalus durissus terrificus
(Q58G94) [17]; Gyroxin analog, Lachesis muta muta (P33589) [18]; Crotalase, Crotalus adamanteus [19]; Ancrod, Ag‐
kistrodon rhodostoma (P26324) [20]; Batroxobin, Bothrops atrox (P04971) [21]; Bilineobin, Agkistrodon bilineatus
(Q9PSN3) [22];TSV-PA, Trimeresurus stejnegeri (Q91516) [23]; LV-PA, Lachesis muta muta (P84036) [24]; PA-BJ, Bo‐
throps jararaca (P81824) [25]. Toxin names were indicated in bold followed by snake species in italic and the Swissprot
accession numbers were represented in parenthesis.
The major symptoms from snakebite affecting the haemostatic system are: (a) reduced
coagulability of blood, resulting in an increased tendency to bleed, (b) bleeding due to the
damage to blood vessels, (c) secondary effects of increased bleeding, ranging from hypovo‐
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laemic shock to secondary-organ damage, such as intracerebral haemorrhage, anterior
pituitary haemorrhage or renal damage and (d) direct pathologic thrombosis and its sequelae,
particularly pulmonary embolism [26].
The venom fibrinogenolytic serine proteases as well as the venom plasminogen activator, share
extensive sequence homology with the thrombin-like venom serine proteases [27] such as
ancrod [20, 28], batroxobin [21, 29], crotalase [30,31], gyroxin-like serine proteases [17],
kallikrein-like enzyme from Crotalus atrox [32] and the protein C activator from A. c. contor‐
trix [33] venoms.
The SVSPs share the conserved catalytic triad formed by the amino acids His, Asp and Ser, six
disulfide bonds and global highly similarities, as seen in Figure 2. In this alignment, the
deduced amino amino acid sequences of gyroxin-like B2.1, B1.3, B1.4, and B1.7 are highly
similar to other SVSPs with several biological functions [17].
In order to predict the biological function of SVSPs, a functional dendrogram was generated
based on the amino acid sequence alignment from Figure 2. Clearly there are subtle differences
among these homologous enzymes that may explain different functions such as: fibrinogeno‐
lytic (group I), Aα fibrinogenases (subgroup I a), Protein C activator and CPI-enzyme (sub‐
group I b), kininogenases (subgroup I c), plasminogen activator (group II), factor V activators
(group III) thrombin-like, or other specific enzymatic activities (Figure 3) [17].
Despite significant sequence identity (50–70%), SVSPs display high specificity toward distinct
macromolecular substrates. Based on their biological roles, they have been classified as
activators of the fibrinolytic system, procoagulant, anticoagulant and platelet-aggregating
enzymes [34]. The procoagulant SVSPs activate FVII, FX and prothrombin [35] and shorten the
coagulation times, while the anticoagulants inactivates factors Va and VIIIa and plays a key
role in controlling haemostasis, Ancrod (from the Malayan pit viper, Calloselasma rhodostoma),
in particular, has been used as an anticoagulant to achieve "therapeutic defibrination" [34].
As it can be seen in Figure 4 (top), the 3D model of gyroxin-like B2.1 shows the catalytic site
(Ser184, His43 and Asp88) superimposed with the catalytic site of thrombin (Ser195, His57 and
Asp102) [36]. The overall structure (bottom) show the typical fold of a serine proteinase in which
the active-site cleft is located at the junction of the two six-stranded β-barrels. Among the
conserved 3D structural features between trypsin-like enzyme and SVSPs are the two β-barrel
subdomains, the orientation of catalytic site and the pattern of Cys residues. In contrast with
other serine proteases, a unique long C-terminal tail of gyroxin are highly conserved only on
SVSPs. In addition, SVSPs are active only as a single chain enzyme while prothrombin is
activated by Factor Xa generating the Light (L) and Heavy (H) chains of active thrombin.
2.1. The role of Protease Activated Receptor (PAR) on serine protease coagulation
Protease-activated receptors (PARs) are members of family of seven-transmembrane G-
protein-coupled receptors (GPCRs). The activation is triggered by the cleavage of the N-
terminus of the receptor by a serine protease, resulting in the generation of a new tethered
ligand that interacts with the receptor within its extracellular loop-2. This ligand binding to
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the core of PARs initiates an intracellular signal transduction pathway, which stimulates
phosphoinositide breakdown and cytosolic calcium mobilization [37].
There are four PARs (PAR-1, PAR-2, PAR-3 and PAR-4), PAR-1, PAR-3 and PAR-4 can be
activated by thrombin while PAR-2 is activated by trypsin and trypsin-like proteases, but not
by thrombin [38]. PAR-1 is important for activation of human platelets by thrombin, but plays
no apparent role in mouse platelet activation [39]. The consensus sequence among all the
Figure 2. Alignment of snake venom serine proteases 1-5) Gyroxin-like B2.1, B1.3, B1.4, B1.5, B1.7 from Crotalus
durissus terrificus (Q58G94, B0FXM1, B0FXM2, EU360953, B0FXM3, respectively). 6) Bilineobin from Agkistrodon bili‐
neatus (Q9PSN3). 7) Crotalase from Crotalus adamanteus. 8) Ancrod from Agkistrodon rhodostoma (P26324). 9) Gyro‐
xin analog from Lachesis muta muta (P33589). 10) Acutobin from Agkistrodon acutus (Q9I8X2). 11) Calobin from
Agkistrodon caliginosus (Q91053). 12) KN-BJ from Bothrops jararaca (O13069). 13) SVSP-1 Venom serine proteinase
from Crotalus adamanteus (Q8UUK2). 14) Catroxase-1 from Crotalus atrox (Q8QHK3). 15) ACC-C Protein C activator
from Agkistrodon contortrix contortrix (P09872). 16) CPI enzyme from Agkistrodon caliginosus (O42207). 17) Dav-PA
from Agkistrodon acutus (Q9I8X1). 18) Catroxase-2 from Crotalus atrox (Q8QHK2). 19) PA-BJ from Bothrops jararaca
(P81824). 20) TSV-PA from Trimeresurus stejnegeri (Q91516). 21) LV-PA from Lachesis muta muta (P84036). 22) Ba‐
troxobin from Bothrops atrox (P04971). Indicated accession numbers are from Swissprot. The lines indicate the disul‐
fide bonds and the catalytic triad (His, Asp and Ser) are represented by *. Toxin names were indicated in bold followed
by snake species in italic and the Swissprot accession numbers were represented in parenthesis.
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human PAR-1 activating peptides is XFXXR, indicating that the second residue (Phe) and fifth
residue (Arg) are critical for the agonist binding and activation [40].
Figure 3. Dendrogram of 34 mature snake venom serine proteases. Toxin names were indicated in bold followed
by snake species in italic and the Swissprot accession numbers were represented in parenthesis. (*) Crotalase toxin se‐
quence was based on [19]. All positions containing gaps and missing data were eliminated from the dataset. There
were a total of 188 positions in the final dataset. The distance was calculated by number of amino-acid differences.
The optimal tree with the sum of branch length = 796.39 and the percentage of replicate trees in which the associated
taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches. Fibrinogenolytic (group
I), Aα fibrinogenases (subgroup I a), Protein C activator and CPI-enzyme (subgroup I b), kininogenases (subgroup I c),
plasminogen activator (group II), factor V activators (group III).
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Figure 4. Gyroxin and bovine a-Thrombin (1mkx). The gyroxin homology model was based on crystallographic
structures of Trimeresurus stejnejeri TSV-PA (1bqy), Agkistrodon acutus AaV-SP I (1op0) and Agkistrodon acutus AaV-SP
II- DAV-PA (1op2). Top: Catalytic tryad superimposition of gyroxin residues (pink) and α-thrombin (blue). Bottom: Two
β-barrel domains formed by β-sheets are depicted in yellow and α-helixes in red. Disulfid bridges are depicted in
green. The residues from active site are showed in pink to gyroxin molecule and blue to activated thrombin.The C-
teminus and N-terminus are indicated to both thrombin heavy (H) and ligth (L) chains and to gyroxin model.
It is known that the inhibitory effects of PAR1 antagonists on platelet aggregation caused by
high concentrations of thrombin are limited but can be enhanced by combination with PAR4-
blocking antibody, suggesting that simultaneous blockade of PAR1 and PAR4 may provide
more effective antithrombotic therapy [41].
An example of snake venom serine protease that acts on coagulation through PAR is gy‐
roxin  (serine  protease  from C.d.terrificus)  that  promotes  platelet  aggregation  through its
involvement with PAR 1 and 4 [42]. In fact, a significant inhibition of the maximum pla‐
telet aggregation effect induced by gyroxin was observed in the presence of inhibitors of
both PAR-1 [SCH79797] and PAR-4 [tcY-NH2]. PAR-1 inhibitor was effective at concentra‐
tion of about two orders of magnitude below than that required for PAR-4 inhibitor, and
the combination of these two inhibitors were not capable to completely inhibit the plate‐
let aggregation induced by gyroxin [42].
2.2. Molecular biology of SVSPs
Batroxobin  (Bothrops  atrox  serine  protease,  E  3C.4.21.29)  is  a  thrombin-like  enzyme  de‐
rived from Bothrops atrox, moojeni venom. In contrast to thrombin which converts fibrino‐
An Integrated View of the Molecular Recognition and Toxinology - From Analytical Procedures to Biomedical
Applications
158
gen  into  fibrin  by  splitting  off  fibrinopeptides  A  and  B,  batroxobin  only  splits  off
fibrinopeptide A [43].
Batroxobin gene spans 8 kilobase pairs and contains five exons and its mature form is encoded
by exons 2 to 5. The catalytic residues of batroxobin, His-41, Asp-86, and Ser-178, are encoded
by separate exons, exons 2, 3, and 5, respectively [44].
The exon/intron organization of the batroxobin gene is different from that of the prothrombin
gene but very similar to those of the trypsin and kallikrein genes. These results indicate that
batroxobin is not a member of the prothrombin family but one of the trypsin kallikrein family.
The snake venom gland is assumed to originate from the submaxillary gland. Therefore,
batroxobin is expected to be a member of the glandular kallikrein family [44].
cDNA libraries of snake venom glands have been constructed from various species and several
clones encoding SVSPs have been isolated and sequenced. SVSPs are one chain proteins
encoded by cDNAs containing an open reading frame (ORF) around 800 bp. The 5’UTRs (5
´untranslated region) are usually short while the 3’UTRs (3´untranslated region) vary in length
and may contain more than 1200 nucleotides [3].
Snake venom serine protease are synthesized as zymogens of ~256–257 amino acids with a
putative signal peptide of 18 amino acids and a proposed activation peptide of six amino acid
residues [3]. In the process of protein export, a central role is played by the signal sequence:
an N-terminal segment that somehow initiates export whereupon it is cleaved from the
zymogen. Three structurally dissimilar regions have been recognized so far: a positively
charged N-terminal region, a central hydrophobic region and a more polar C-terminal region
that seems to define the cleavage site [45].
The organization of batroxobin gene, batroxobin cDNA and gyroxin-like B2.1, B1.3, B1.5 and
B1.7 [17, 36, 44] are shown in Figure 5.
Figure 5. Organization of the batroxobin genomic gene, cDNA of Batroxobin and gyroxin-like B2.1, B.1.3, B1.4, B1.5
and B1.7 from C.d.terrificus.Blue boxes denote the location of exons of batroxobin genomic gene (X12747), the blue
bars denote noncoding regions of introns. Orange boxes denote the location of exons of cDNA of Batroxobin (J02684)
and gyroxin-like B1.3, B1.4, B1.5, B1.7 from C.d.terrificus (EU360951; EU360952; EU360953 and EU360954, respective‐
ly). In case of clone B2.1, only a partial sequence was obtained (GenBank accession number AY954040). The lack of
exon 4 in B1.5 clone is because this clone is truncated by the insertion of a stop codon in translated sequence at the
position 472 pb due to the joining of the exon 3 and exon 5.
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Gyroxin-like B2.1 has a shorter 3´UTR compared with other clones. The lack of exon 4 in
gyroxin-like B1.5 is because this clone is truncated by the insertion of a stop codon in translated
sequence at the position 472 pb due to the joining of the exon 3 and exon 5 [17].
In Figure 6, the alignment of nucleotide sequences from gyroxin-like B1.3 and B2.1 revealed
that clone B1.3 contains two consensus motifs for hypothetical poly(A+) signals (5’- AATAAA
-3’) at positions 929 and 1380 bp, whereas the B2.1 sequence contains only the first poly(A+)
signal at the position 857 bp and has a shorter 3’UTR and poly(A+) tail [17].
The transcription of mRNA can be related with polyadenilation sites on 3´UTR (3´untranslated
region). The presence of short and long 3’UTRs was also described for myogenin, Xmyog U1
and Xmyog U2 from Xenopus laevis (Xmyog U2) [46] that contains one and two consensus motifs
for a poly(A+) signal, respectively. These results suggest the presence of at least, two different
poly(A+) signals in Xmyog U2, generating two transcripts with different 3’ ends.
Figure 6. Alignment of nucleotide sequences from gyroxin-like B1.3 (EU360951) and B2.1 (AY954040). Coding
region for signal peptide and propeptide is indicated in dark grey. Start codon and stop codons are in bold. The ma‐
ture coding region is indicated in white. The mutations between B1.3 and B2.1 sequences are indicated by a box line
and differences in nucleotides are in bold. Light grey encompasses the 3’ UTR. B1.3 hypothetical poly A+ signal (929–
934 bp), B1.3 poly A+ signal (1380–1385 bp) and B2.1 poly A+ signal (857–862 bp) are in bold. Dashes represent gaps
introduced for optimal sequence alignment.
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Similarly, the presence of two signals of polyadenylation in gyroxin-like B1.3, suggests that
two mRNAs could be transcripted with longer or smaller 3’ UTR. Gyroxin-like B2.1 has only
one signal of polyadenilation, showing a shorter 3´UTR than gyroxin-like B1.3 (Figure 5) [17].
2.3. Recombinant serine protease expression
Due to the great biotechnological potential of toxins present in the snakes venoms, many
efforts have been made in order to clone and express those toxins in order to study its bi‐
ological  activity.  However,  the  study  of  their  properties  is  often  hampered  due  to  the
small amount obtained and the difficulty of getting the animals to extract the poison, and
when these are not the case, many toxins require several purification steps that result in a
lower final yield. For these reasons, many toxin genes have been isolated, cloned and ex‐
pressed in  heterologous systems.  This  methodology not  only  make possible  to  obtain  a
large amount of toxins, but also enable amino acids modification by specific mutations in
their DNA sequence. Thus, whole molecules may be broken down in order to study the
function of its domains [47, 48], as well as amino acid residues may be exchanged for to
study its role in substrate binding [49, 50].
2.3.1. Expression of serine protease on prokaryotic cells
Currently, the most used system to express snake toxins has been bacteria. However, the
expression of recombinant SVSPs using E. coli as a host may result in expression of insoluble
proteins that must be refolded in vitro in order to be activated. Batroxobin, for example, was
the first SVSP to be expressed in insoluble form in E. coli and subsequently refolded to yield
an active enzyme [51]. The plasminogen activator from T. stejnegeri was expressed in E. coli,
but had to undergo a a denaturation-renaturation process in appropriate redox conditions to
allow for the correct formation of disulfide bridges. Using an innovative method, a kallikrein-
like protease (Tm-5) from the snake venom Taiwan habu (Trimeresurus mucrosquamatus), was
expressed in E.coli by placing a polyhistidine-tag linked to an autocatalyzed site based on the
cleavage specificity of the serine protease. The autocatalytic cleavage of Tm-5 from the
polyhistidine-tagged fusion protein resulted in an active recombinant enzyme [53].
Acutin and mucrosobin, enzymes with fibrinogen-clotting and β-fibrinogenase activities
respectively, were successfully expressed in E. coli [54,55]. The expression of a SVSP in E.coli,
rCC-PPP, an isoform of cerastocytin from Cerastes cerastes with platelet-aggregating activity
was reported [56]. After refolding, the recombinant enzyme showed to be a potent platelet
proactivator and to clot fibrinogen.
2.3.2. Expression of serine protease on eukaryotic cells
In general SVSPs are glycosylated and this post-translational modification is important to the
toxin activity, besides that, when expressed in E. coli those toxins frequently results in insoluble
or inactive forms. Therefore the eukaryotic system such as yeast, mammalian cells and
baculovirus expression system in insect cells have been explored, and although the number of
works using this systems are small, they are growing substantially, mainly because of its
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superior refolding machinery and post-translational modifications (e.g. phosphorylation and
glycosylation) [57].
The recombinant Haly-PA was successfully expressed using the baculovírus expression
system, displayed an indirect fibrinogenolytic activity depending on the presence of plasmi‐
nogen and cleaved the plasminogen to generate the active plasmin. These results indicate that
Haly-PA is a plasminogen activator and displays fibrinogenolytic activity through conversion
of plasminogen to plasmin [58].
The recombinant Batroxobin from Bothrops atrox moojeni venom –expressed in Pichia pastoris,
was able to coagulate plasma in a dose dependent manner. However, its molecular weight was
higher than the native protein, indicating yeast-type carbohydrate in its structure [59].
The expression of a glycoprotein Gyroxin-like B2.1 from Crotalus durissus terrificus venom was
reported in COS-7. In order to promote the secretion of this toxin to the culture medium it was
fused to the IgK-chain secretion signal peptide at the N terminus [17]. The recombinant
Gyroxin expressed in COS-7 cell (Figure 7-Western blot, lane 1) showed the same electropho‐
retic pattern of the native Gyroxin purified from the venom (Figure 7-Western blot, lane 2).
Recombinant Gyroxin-like B2.1 was successfully achieved with esterase activity in the
conditioned culture medium, as revealed by immunoblot of secreted protein and standard
anti-crotalic serum from Butantan Institute (Figure 7).
Figure 7. Esterase activity assay of recombinant Gyroxin purified by Benzamidine Sepharose from the supernatant of
lysate and conditioned culture medium over 24 h of transfected COS-7 cells with pED-Gyro. Supernatant lysate and
conditioned culture medium of untransfected COS-7 cells were used as negative controls. Porcine pancreas Trypsin
and purified Gyroxin from C.d.terrificus venom were used as positive controls. 1- Western blot of COS-7 cells extract
transfected with pED-Gyro., 2- 0.05 mg of Gyroxin purified from C.d.terrificus (positive control). The primary antibody
was anti-crotalic serum from Butantan Institute and the reaction was detected with secondary antibody conjugated to
horseradish peroxidase.
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2.4. Therapeutic and diagnostic use
Due to the properties of SVTLEs, they have been extensively investigated over the last decade
for potential therapeutic and diagnostic use and some of them are summarized in Table 1,
based on [6, 60-62].
In  this  regard,  ancrod  [63]  from  Calloselasma  rhodostoma  venom,  whose  current  brand
name  is  ViprinexTM,  was  approved  in  2005  in  the  fast  track  program  of  United  States
Food and Drug Administration (FDA) for investigating its use in patients suffering from
acute ischemic stroke [64].
This program is currently undergoing phase III, where the patients received a one-time, 2-3
hour infusion of ancrod or placebo within six hours of the initial symptom onset of their
ischemic stroke, and are then followed for three months to collect information on their
functional status. Since then, many research articles about the use of ancrod in ischaemic stroke
has been published [63,65-68].
Another thrombin-like enzyme that has been used clinically is Batroxobin (Defibrase®) from
Bothrops atrox venom. In a randomized clinical trial using this toxin in association with aspirin
indicated a reduced rate of restenosis in patients with diabetes undergoing angioplasty for
lower-limb ischemia [69]. In another experiment, the combination of batroxobin and tranexa‐
mic acid in 80 adolescent patients undergoing scheduled idiopathic scoliosis surgery was able
to markedly reduce blood loss and allogeneic blood transfusion [70]. Others trials involving
batroxobin include deep vein thrombosis [71] treatment of hyperfibrinogenemia for secondary
stroke prevention [72] and acute ischemic stroke [73].
Drug/trade name® Target and function/treatment Source
Ancrod (Viprinex) Fibrinogen inhibitor/stroke Agkistrodon rhodostoma
(Malayan pit viper)
Batroxobin (Defibrase) thrombin and protrhombin inhibitor/acute cerebral
infarction, unspecific angina pectoris
Bothrops moojeni
Hemocoagulase thrombin-like effect and thromboplastin activity/
prevention and treatment of haemorrhage
Bothrops atrox
Protac/protein C
activator
protein C activator/clinical diagnosis of
haemostatic disorder
Agkistrodon contortix contortix
(American copperhead)
Reptilase diagnosis of blood coagulation disorder Bothrops jararaca (South American
lance adder)
RVV-V Proteolytic activation of factor V Daboia ruselli
Table 1. Clinical applications and diagnostic kits from snake venom serine proteases.
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Since SVSPs shortens the bleeding time and clotting time, by promoting coagulation locally at
the site of bleeding, combination of enzymes is also employed for the prevention or treatment
of hemorrhage such as might be encountered in surgeries. In this regard, hemocoagulase, a
mixture of purified enzymes isolated from the venom of Bothrops atrox is another example in
clinical trials [74,75]. It has two different enzymatic activities, one which promotes blood
coagulation by converting prothrombin to thrombin (thromboplastin like enzymes) and the
other that causes a direct transformation of fibrinogen to fibrin monomer.
Despite its use in clinical application, some SVSPs have also been explored as a diagnostic tool,
mainly because they are not inhibited by heparin and therefore they can be used to test plasma
samples containing this anticoagulant or to remove fibrinogen from samples containing
heparin. In this context, Reptilase®, a thrombin-like serine protease isolated from the venom
of Bothrops atrox is used to assess blood fibrinogen and fibrinogen degradation products
[76,77]. It is useful to check whether a prolonged thrombin time is caused by the presence of
heparin in the sample. However, the reptilase time is rarely performed in isolation and
therefore, the results of this test should be considered together with other tests and in particular
the thrombin time.
It is important to point out that the name “reptilase” was first described in 1958 [78] for an
extract with the fibrinogen clotting activity from the venom of Bothrops jararaca and sometimes
t his term has also been described as a synonymous of “batroxobin” from the venom of Bothrops
moojeni and Bothrops atrox.
Protac®, a serine protease from Agkistrodon contortrix venom is another example that has found
a broad application in diagnostic practice for the determination of disorders in the protein C
(PC) pathway. Unlike thrombin-catalyzed PC activation reaction which requires thrombomo‐
dulin as a cofactor, Protac® directly converts the zymogen PC into the catalytically active form
which can easily be determined by means of coagulation or chromogenic substrate techniques
[79-81].
Due to the capability of a serine protease extracted from Russels´s viper (Daboia ruselli) venom
(RVV-Vα) to activate Factor V, and since activated factor V is not stable and loses its activity
within 20 hours at 37° C, RVV-V has been used to destabilize and selectively inactivate factor
V in plasma. Therefore, it has been used to prepare a routine reagent for factor V determination.
Studies have demonstrated the ability of the Prothrombinase-induced clotting time (PiCT)
assay, which uses RVV-V among its components, to determine activities of both direct and
indirect thrombin inhibitors in a linear manner over a wide concentration range [60-62].
While the original native snake venom compounds are usually unsuitable as therapeutics,
interventions by medicinal chemists as well as scientists and clinicians in pharmaceutical
R&D  have  made  it  possible  to  use  snake  toxins  as  therapeutics  for  multiple  disorders
based  on  the  available  structural  and  functional  information.  Therefore,  snake  venoms,
with their  cocktail  of  individual  components,  have great  potential  as  therapeutic  agents
for human diseases [6].
An Integrated View of the Molecular Recognition and Toxinology - From Analytical Procedures to Biomedical
Applications
164
2.4.1. Serine protease inhibitors
Most animal species synthesize a variety of protease inhibitors with different specificities,
whose function is to prevent unwanted proteolysis. They generally act by unabling access of
substrates to the proteases’active site through steric hindrance. Proteases are also involved in
various disease states such as the destruction of the extracellular matrix of articular cartilage
and bone in arthritic joints is thought to be mediated by excessive proteolitic activity [82].
Among the enzymes involved in extracellular matrix degradation, a few serine proteases
(elastase, collagenase, cathepsin G) are able to solubilize fibrous proteins such as elastin and
collagen [83,84].
Given the specific recognition by proteases of defined amino acid sequences, it may be possible
to inhibit these enzymes when they are involved in pathological processes. Potent inhibitors
have the potential to be developed as new therapeutic agents. In vertebrates for example serine
protease inhibitors, have been studied for many years and they are known to be involved in
phagocytosis, coagulation, complement activation, fibrinolysis, blood pressure regulation.
Moreover, some of the protease inhibitors isolated from invertebrate sources are quite specific
towards individual mammalian serine proteases. This also offers huge opportunities for
medicine. Thus, the development of non-toxic protease inhibitors extracted from invertebrates
for in vivo application may be quite important [82].
The last decade, drug discovery in leeches has opened the gate for new molecules to treat
emphysema, coagulation, inflammation, dermatitis and cancer. Also other invertebrates, such
as insects, harvest potential interesting molecules, such as serine protease inhibitors that can
be exploited by the medical industry [85].
3. Conclusions
Snake venom serine proteases have several different functions and have found most use in
medicine in blood coagulation system. These enzymes are used in several ways as tools in
basic research helping to elucidate the relation of structure- function of coagulant proteins and
their interactions with platelets or in experimental models of haemostatic alterations.
Some SVSPs have already been found to be a commercial use in coagulation diagnostic and
some of them are used either to influence physiological homeostasis or as a form of supportive
treatment in haemostatic disorders and micro vascular surgery promoting cicatrization.
Despite the high homology of serine proteases and even sharing the same target, small
differences in their amino acids composition may lead significant binding intensity causing
differences in their biological effects. Therefore, even isoforms of those molecules in the same
organism must be explored. Many animals besides snakes also possess serine proteases that
are used for attack or defense purposes, such as scorpions, bees, spiders and even the exotic
platypuses which make 26 different kinds of serine proteases [86].
Therefore, the diversity of those toxins is extensive and demand many research to elucidate
their function and potential clinical applications
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